Compare CALC & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | MDRR |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 18.3M |
| IPO Year | 2020 | 2015 |
| Metric | CALC | MDRR |
|---|---|---|
| Price | $1.70 | $11.00 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 79.0K | 6.9K |
| Earning Date | 05-13-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.43% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.74 |
| Revenue | N/A | ★ $10,396,618.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.32 |
| Revenue Growth | N/A | ★ 6.79 |
| 52 Week Low | $0.44 | $9.47 |
| 52 Week High | $7.20 | $14.52 |
| Indicator | CALC | MDRR |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 44.31 |
| Support Level | $0.51 | $10.85 |
| Resistance Level | $2.31 | $12.23 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 7.46 | 14.13 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.